INTRODUCTION {#S5}
============

Obesity is associated with low-grade chronic inflammation, evidenced by immune cell infiltration and activation and proinflammatory cytokine secretion in insulin-responsive tissues, which is postulated to contribute to obesity-related insulin resistance and development of type 2 diabetes.^[@R1]^ Consistent with this, individuals with insulin resistance and diabetes have elevated levels of proinflammatory cytokines, such as tumor necrosis factor--α (TNFα).^[@R2]^ Previous studies showed that obesity promotes accumulation of M1-like (CD11b+F4/80+CD11c+) macrophages in visceral adipose tissue (VAT),^[@R3],[@R4]^ which contribute to inflammation and insulin resistance.^[@R5],[@R6]^ Macrophage activation is largely driven by interactions with T cells, which increase in AT of obese mice.^[@R7]--[@R9]^ CD8+ T cells and proinflammatory interferon-γ (IFNγ)--producing CD4+ T cells (T helper I \[T~H~1\] cells), increase in VAT of obese mice compared to lean controls,^[@R10]--[@R13]^ whereas regulatory T cells (T~reg~) and interleukin-4 (IL-4)--secreting CD4+ T cells (T~H~2), which have anti-inflammatory effects, are reduced.^[@R14],[@R15]^

Increased VAT inflammatory cells impair preadipocyte/adipocyte functions, with reduced lipogenesis and increased lipolysis,^[@R16]--[@R18]^ which leads to increased circulating free fatty acids^[@R19]^ and subsequent ectopic fat deposition in skeletal muscle (SM).^[@R20],[@R21]^ SM is the primary organ for maintaining whole-body glucose homeostasis, accounting for \~80% of whole-body glucose disposal.^[@R22],[@R23]^ Lipid accumulation in SM is associated with insulin resistance in humans and animals.^[@R24]--[@R26]^ Previous studies focused on intramyocellular lipid content (triglycerides accumulated within muscle cells) and showed associations with metabolic risk factors in humans.^[@R27]--[@R29]^ Research has also shown existence of extramyocellular adipose tissue (EMAT) compartments. However, studies on EMAT are limited. EMAT includes intermuscular adipose tissue (IMAT), located between muscle fibers, and perimuscular adipose tissue (PMAT, or subfascial AT), primarily located around large muscles. EMAT content was increased in obese humans^[@R30]^ and associated with systemic insulin resistance,^[@R31],[@R32]^ but the mechanisms remain largely unknown.

Obesity causes macrophage accumulation in SM, which may contribute to SM inflammation,^[@R33]--[@R37]^ but reports are not consistent. Two groups found low levels of macrophages in SM of obese humans.^[@R38],[@R39]^ We recently demonstrated T cell infiltration into SM of high-fat diet (HFD)--fed mice^[@R40]^; however, T cells subsets in SM of lean and obese mice, and their contribution to SM inflammation and insulin resistance, have not been characterized. Furthermore, the mechanism has not been elucidated. CD11a, which is also known as lymphocyte function--associated antigen--1 (LFA-1), plays an important role in lymphocyte transendothelial migration and activation.^[@R41]^ CD11a was implicated in obesity-associated AT inflammation and T cell accumulation.^[@R42]^ We thus hypothesized that CD11a mediates T cell recruitment into SM of obese mice. T cells subsets in SM of lean and obese mice, and their contribution to SM inflammation and insulin resistance, have not been characterized. We hypothesized that proinflammatory T~H~1 cells may induce SM metabolic dysfunction. SM fibers express IFNγ receptor,^[@R43]^ which could further activate signal transducer and activator of the transcription--1 (STAT1) via Janus tyrosine kinases (JAK)--1 and --2.^[@R44]^ We thus hypothesized that T~H~1 cells contribute to SM inflammation and insulin resistance via their main cytokine---IFNγ---and the JAK/STAT pathway.

In this study, we demonstrated the localization of immune cells within skeletal muscle with a focus on IMAT and PMAT. We further characterized macrophages and T cells in SM of lean and obese mice and validated our results in humans. In addition, we investigated a potential mechanism of activated T cell--mediated SM inflammation and insulin resistance.

MATERIALS AND METHODS {#S6}
=====================

Mice {#S7}
----

Male C57BL/6J wild-type (WT) mice were obtained from The Jackson Laboratory (Bar Harbor, ME). Mice were fed normal chow diet (ND; 12% kcal from fat; Picolab Rodent Diet 5010, Purina Mills) after weaning until 8 weeks old. Starting at 8 weeks of age mice were fed western high-fat diet (HFD) (41% kcal from fat; Dyet 112734, Dyets Inc.) for 2--24 weeks or maintained on ND for the same period. CD11a-deficient (CD11a−/−)^[@R42]^ and C57BL/6NHsd control mice (Harlan Laboratories) were fed ND or HFD for 16 weeks. Animal studies and procedures were approved by the Institutional Animal Care and Use Committee of Baylor College of Medicine. For micro--computed tomography (micro-CT) studies, C57BL/6J mice fed ND or 60%HFD (60% kcal fat; D12492, Research Diets) for 12 weeks were donated by Willa Hsueh (Houston Methodist Research Institute, Houston, TX). No randomization was used to allocate the animals to experimental groups. The investigator was not blinded to the group allocation.

Micro-CT studies {#S8}
----------------

Mice were scanned with high-resolution micro-CT (Siemens Inveon Preclinical Multimodel SPECT/CT) using the Inveon Acquisition Workplace software package (Siemens). A filtered back projection algorithm was used for reconstruction, resulting in reconstructed isotropic voxel size of 0.205 mm. Excised mouse legs were imaged at higher resolution (isotropic voxel size=0.108 mm).

Micro-CT data for mice were analyzed with custom-built software implemented in Matlab Version 7.8.0 (64-bit). AT was quantified semiautomatically using region of interest--based approach.^[@R45]^ IMAT and PMAT were quantified in 3 micro-CT slices of the thigh ([Supplemental Figures 4--5](#SD1){ref-type="supplementary-material"}) and summed in mm^2^. Calf IMAT/PMAT was obtained from a single slice at midcalf. Abdominal visceral AT (VAT) and abdominal subcutaneous AT (SAT) were quantified in 1 abdominal micro-CT slice in the region between L4 and L5 ([Supplemental Figure 6](#SD1){ref-type="supplementary-material"}).

Metabolic studies {#S9}
-----------------

Plasma glucose and insulin from mice after 6-hour fast were measured at Baylor College of Medicine Mouse Metabolism Core. Insulin resistance was estimated by HOMA-IR.^[@R40]^ Fasted mice were injected intraperitoneally with 1.5 U/kg regular human insulin or saline. After 10 minutes, mice were euthanized, and quadriceps muscle tissues harvested.

Flow cytometry {#S10}
--------------

The whole quadriceps SM (referred to as "SM"), which included muscle fibers, IMAT and PMAT, from mouse hind legs was minced and digested at 37°C with 450 U/ml collagenase type I (Worthington Biochemical Corporation) for 45 minutes. Digested tissues were strained through 100 µm--pore filters, and cells recovered by centrifugation. Cells were incubated in CD16/CD32 antibody (BD Pharmingen, catalog \#553142) to block Fc receptors and stained with Fixable Viability Dye eFluor 780 (eBioscience, catalog \#65-0865) and antibodies specific for CD45 (BD Pharmingen, catalog \#553080), CD3 (BD Pharmingen, catalog \#553066), CD4 (BD Pharmingen, catalog \#553052), CD8 (BD Pharmingen, catalog \#561094), CD11b (BD Pharmingen, catalog \#553311), F4/80 (eBioscience, catalog \#17-4801), CD11c (eBioscience, catalog \#45-0114), and CD25 (eBioscience, catalog \#17-0251), or isotype controls. For intracellular staining, cells were incubated with Leukocyte Activation Cocktail with BD GolgiPlug (BD Pharmingen) in complete RPMI medium (Invitrogen) containing 10% FBS for 5 hours at 37°C. Cell suspensions were fixed and permeabilized with BD Cytofix/Cytoperm kit (BD Biosciences) and stained with anti--IFN-γ (BD Pharmingen, catalog \#554412). To detect T~reg~ cells, muscle cells were incubated in Fixation/Permeabilization solution (eBioscience) for 1 hour at room temperature, washed, and stained with anti--FoxP3 (eBioscience, catalog \#12-5773). Flow cytometry analysis was performed with Beckman Coulter Kaluza 1.2 software.

Immunohistochemistry {#S11}
--------------------

Quadriceps tissues were fixed in Z-fix (Anatech Ltd), embedded in paraffin, and sectioned for staining with hematoxylin/eosin, 1:50 dilution of monoclonal antibody to Mac-3 (clone M3/84, BD Pharmingen, catalog \#550292), or IgG-isotype control (BD Pharmingen, catalog \#559072) followed by biotinylated anti-rat IgG antibody (Vector Laboratories, catalog \#BA-4001), or 1:20 dilution of polyclonal antibody to CD3 (Abcam, catalog \#ab5690), followed by biotinylated goat anti-rabbit antibody (Abcam, catalog \#ab128978). Tissues were incubated with Vectorstain Elite ABC kit and DAB substrate (Vector Laboratories).

In vivo neutralization of CD11a {#S12}
-------------------------------

C57BL/6NHsd mice on HFD for 12 weeks were injected intraperitoneally with 200 µg KBA (neutralizing antibody to mouse CD11a, rat IgG2a) or rat IgG2a isotype control (eBioscience, catalog \#16-4321) on alternate days for 9 injections. Mice were sacrificed 2 days after last injection, and quadriceps tissues harvested for RT-PCR and flow cytometry.

Baricitinib treatment {#S13}
---------------------

Mice fed HFD for 2 months were orally administered vehicle or 10 mg/kg body weight INCB028050 (baricitinib; MedChemexpress) suspended in 0.5% methylcellulose once daily for 3 weeks. On day 18 after the initiation of treatment, mice were fasted for 6 hours followed by intraperitoneal injection of 1.5 U/kg regular human insulin for insulin tolerance test. On day 22, mice were sacrificed, and SM and perigonadal adipose tissue collected for RT-PCR and flow cytometry.

Naïve CD4+ T cell and T~H~1 cell culture {#S14}
----------------------------------------

Naïve CD4+ T cell-- and T~H~1-conditioned media were obtained as described.^[@R40]^

Cell culture {#S15}
------------

Confluent C2C12 cells (ATCC) were induced to differentiate by replacing DMEM supplemented with 10% FBS (Hyclone) with 2% horse serum DMEM. After 4 days, differentiated myotubes were treated for 48 hours with naïve CD4+ T cell-- or T~H~1-conditioned medium with or without 10 ng/ml anti-IFNγ antibody or 1 µM JAK inhibitor I (Calbiochem), and mRNA was isolated. In a separate experiment, after treatment for 48 hours in serum-free medium, C2C12 myotubes were treated with PBS or 100 nM insulin for 15 minutes, lysed, and collected for Western blotting.

Human studies {#S16}
-------------

Lean (BMI=21.7±1.7 kg/m^2^; n=15) and obese (BMI=36.0±4.8 kg/m^2^; n=12) normoglycemic (HbA1c ≤6.5%) participants in a cross-sectional study (ORIGINS) at the Translational Research Institute for Metabolism and Diabetes ([Supplemental Table 1](#SD1){ref-type="supplementary-material"}) had blood drawn and underwent biopsy of the vastus lateralis. The study was approved by the Florida Hospital Institutional Review Board. All subjects signed informed consents prior to the study.

RNA isolation and quantitative RT-PCR {#S17}
-------------------------------------

Total RNA was isolated using TRIzol reagent (Invitrogen) per manufacturer's instructions from SM (including muscle fiber, IMAT, and PMAT), "muscle" (including muscle fiber and IMAT), and PMAT. Gene expression was examined by quantitative RT-PCR and expressed as relative mRNA levels compared with 18S rRNA internal control. Samples with low quantity of 18S were excluded from the analysis.

Western blotting {#S18}
----------------

SM and cells were homogenized in Complete Lysis-M EDTA-free buffer (Roche Applied Science). Protein concentration was measured using the BCA protein assay kit (Pierce Biotechnology). Proteins were subjected to electrophoresis in polyacrylamide 4--12% Bis-Tris Gels (Invitrogen) and transferred to PVDF membranes. After blocking with 5% BSA in Tris-buffered saline containing 0.1% Tween 20 for 2 hours, membranes were immunoblotted with serine^473^-phosphorylated Akt (P-Akt), tyrosine^701^-phosphorylated STAT1 (P-STAT1), total Akt, or total STAT1 antibodies (Cell Signaling Technology). After incubation with secondary antibody conjugated to horseradish peroxidase, antibody-bound proteins were detected using Pierce ECL 2 Substrate reagent (Thermo Fisher Scientific). Bands were scanned and quantified using a STORM 840 (Amersham Biosciences).

Statistics {#S19}
----------

All data are represented as means±standard error of the mean. Statistical analyses were performed using GraphPad Prism 5.0 and SAS 9.3. All data were tested for normal distribution and equivalence of variances. Comparisons between 2 groups were made using Student's t-test for samples with normal distribution and equivalence of variances. Otherwise, nonparametric Mann-Whitney tests were used. Significance was defined as p≤0.05. Data for IMAT/PMAT, VAT, and SAT are not normally distributed and are reported as median (interquartile range). p-values were computed using the nonparametric Kruskal--Wallis test. For correlation analysis, Pearson correlation coefficients were calculated. Two-way ANOVA was used to assess the HFD-induced changes in gene expression between PMAT and "muscle" and the response to insulin in vehicle control-- and baricitinib-treated mice.

RESULTS {#S20}
=======

T cell and macrophage markers are upregulated in SM of obese humans {#S21}
-------------------------------------------------------------------

We first examined obesity-induced changes in inflammatory markers in human SM by comparing the expression of T cell and macrophage markers in vastus lateralis biopsies from lean and obese normoglycemic humans ([Supplemental Table 1](#SD1){ref-type="supplementary-material"}) by RT-PCR. Consistent with previous studies,^[@R36],[@R46]^ macrophage marker CD11b was significantly increased in SM of obese humans compared to lean controls ([Figure 1](#F1){ref-type="fig"}). Proinflammatory CD11c and MCP-1 gene expression was also higher, although those results were not statistically significant because of large variation in obese group. Additionally, we observed the upregulation of T cells markers. CD4, CD8, and RANTES were all significantly increased in SM of obese humans ([Figure 1](#F1){ref-type="fig"}). Our results thus suggest that obesity in humans results in increases in both macrophage and T cell markers.

Macrophage infiltration precedes T cell accumulation in SM during the development of obesity in mice {#S22}
----------------------------------------------------------------------------------------------------

Next, using HFD-induced obese mouse models, we further examined dynamic changes of immune cells in SM. Similarly to in obese humans, HFD feeding for 12 weeks in mice resulted in upregulation of macrophage (F4/80, CD11c) and T cell (CD3, CD8) markers in quadriceps SM ([Supplemental Figure 1](#SD1){ref-type="supplementary-material"}), consistent with other reports.^[@R33],[@R36],[@R37],[@R40]^ SM isolated from these HFD-fed mice also had significant increases in the expression of inflammatory cytokines (IL-12β, IL-18, TNFα, and IFNγ) and chemokines (MCP-1 and RANTES) ([Supplemental Figure 1](#SD1){ref-type="supplementary-material"}). We then examined dynamic changes of immune cells in SM as obesity progressed by comparing mice fed HFD for 2--20 weeks with age-matched ND-fed mice. We performed flow cytometric analysis by gating the viable CD45+ cells and further identified CD11b+F4/80+ cells (total macrophages) and CD11c+ cells (M1-like macrophages) within the CD11b+F4/80+ fraction ([Supplemental Figure 2A](#SD1){ref-type="supplementary-material"}). In the viable CD45+ cells, we quantified CD3+ T cells and CD4+ and CD8+ subsets within the CD3+ fraction ([Supplemental Figure 2B](#SD1){ref-type="supplementary-material"}). Total macrophage and M1 macrophage numbers were significantly upregulated within 2 weeks on HFD ([Figures 2A--B](#F2){ref-type="fig"}). In contrast, T cell numbers were unchanged during the first 6 weeks, but markedly increased at 8 weeks after HFD initiation ([Figure 2C](#F2){ref-type="fig"}). We then characterized subsets of SM-associated T cells in mice fed HFD or ND for 12 weeks. Both CD4+ and CD8+ T cell numbers were significantly upregulated in SM of obese mice ([Figure 2D](#F2){ref-type="fig"}). We further made the novel observation that the proportion of CD25+FoxP3+ regulatory T cells (T~reg~) was diminished 2.5-fold within the CD4+ T cell population. We also confirmed our previous results showing the induction of proinflammatory T~H~1 cells in SM of HFD-fed compared to ND-fed mice (40) ([Figure 2D](#F2){ref-type="fig"}).

T cells and macrophages are predominantly located in PMAT and IMAT {#S23}
------------------------------------------------------------------

In addition to muscle fibers, quadriceps SM consists of adipose tissue between muscle fibers (IMAT) and directly connected to muscle (PMAT) ([Figure 3A](#F3){ref-type="fig"}). Immunohistochemistry on quadriceps sections from ND-fed mice showed that Mac3+ macrophages and CD3+ T cells are few and located between muscle fibers ([Supplemental Figure 3](#SD1){ref-type="supplementary-material"}). In contrast, SM of mice that were fed HFD for 12 weeks had increased Mac3+ macrophage and CD3+ T cell numbers, which were primarily localized in PMAT and IMAT in clusters surrounding adipocytes (crown-like structures) ([Figures 3B--C](#F3){ref-type="fig"}). Next, we separated the quadriceps SM into PMAT and "muscle" and compared the inflammatory gene expression. While PMAT contained only the adipose tissue, "muscle" was a combination of muscle fibers and IMAT, because of difficulty in separating IMAT from muscle fibers. RT-PCR revealed upregulation of macrophage-associated F4/80, CD11c, MCP-1, and TNFα and T cell--associated CD3, CD4, CD8, RANTES, and IFNγ in both "muscle" and PMAT of obese mice compared to "muscle" and PMAT of lean mice ([Figure 3D](#F3){ref-type="fig"}). Furthermore, in both obese and lean mice, most of the inflammatory markers were higher in PMAT than in "muscle," which also included IMAT. However, it was difficult to examine whether these inflammatory marker levels were different between PMAT and IMAT since it was not feasible to separate IMAT from muscle fibers and IMAT accounted for only a small portion of "muscle." In addition, the HFD-induced increases in the inflammatory markers were greater in PMAT than in "muscle" ([Figure 3D](#F3){ref-type="fig"}). Examination of dynamic changes showed that F4/80 and CD11c expression was unchanged in "muscle" during 4 weeks on HFD and significantly increased after 6 weeks on HFD compared to ND ([Figure 4A](#F4){ref-type="fig"}). In contrast, within PMAT, F4/80 mRNA level was significantly higher after only 2 weeks, and CD11c mRNA level was markedly upregulated at 4 weeks on HFD ([Figure 4B](#F4){ref-type="fig"}). Initial CD3 expression was comparable between lean and obese mice for the first 6 weeks in both "muscle" and PMAT and increased 17-fold in PMAT but only 2-fold in "muscle" at 8 weeks on HFD ([Figures 4A--B](#F4){ref-type="fig"}). Our results suggest that in obesity, SM inflammation primarily occurs in SM adipose tissue depots, with early increases in macrophages, followed by T cell accumulation.

IMAT and PMAT accumulation is highly correlated with insulin resistance in obesity {#S24}
----------------------------------------------------------------------------------

Next, we measured the amount of IMAT/PMAT in the thigh and calf, VAT, and SAT of mice by micro-CT ([Supplemental Figures 4--6](#SD1){ref-type="supplementary-material"}). IMAT/PMAT increased 25-fold, while VAT increased 6-fold, and SAT increased 9-fold in obese mice compared to lean mice ([Supplemental Table 2](#SD1){ref-type="supplementary-material"}). Thigh and calf IMAT/PMAT and total IMAT/PMAT were positively correlated with body weight, abdominal VAT, and SAT ([Table 1](#T1){ref-type="table"}). Obese mice were more insulin resistant by assessment of increased HOMA-IR ([Supplemental Figure 7A](#SD1){ref-type="supplementary-material"}) and decreased insulin-stimulated P-Akt level in quadriceps SM compared to lean mice ([Supplemental Figure 7B](#SD1){ref-type="supplementary-material"}). Total IMAT/PMAT was significantly positively correlated with fasting glucose, fasting insulin, and HOMA-IR and was negatively associated with P-Akt level in SM ([Table 1](#T1){ref-type="table"}). Total IMAT/PMAT was positively correlated with T cell number (r=0.724; p=0.042). Our data suggested that accumulation of IMAT/PMAT and expansion of SAT and VAT depots correlates with SM inflammation and insulin resistance.

T cell recruitment into SM in obesity is mediated by CD11a {#S25}
----------------------------------------------------------

To study the mechanism of T cell accumulation in SM in obesity, we tested the involvement of CD11a using HFD --fed CD11a−/− mice. Compared to obese WT, obese CD11a−/− mice had significantly reduced expression of CD3, RANTES, MCP-1, and TNFα in SM ([Figure 5A](#F5){ref-type="fig"}). Flow cytometric analysis also revealed significant reduction in the number of T cells, including CD4+ and CD8+ T cells. On the other hand, macrophage number was not different between the two groups of mice ([Figure 5B](#F5){ref-type="fig"}). Similarly, neutralization of CD11a with KBA in obese WT mice reduced CD8+ T cell numbers in SM without affecting macrophage numbers, as measured by flow cytometry ([Figure 5C](#F5){ref-type="fig"}). Although CD11a blockade did not change CD3 expression in "muscle," CD3 mRNA level was drastically reduced in PMAT ([Figure 5D](#F5){ref-type="fig"}). All these data suggest involvement of CD11a in T cell accumulation in SM, particularly SM-associated fat depots.

T~H~1 cells directly impair SM cell metabolic functions through IFNγ-induced JAK/STAT pathway {#S26}
---------------------------------------------------------------------------------------------

Because of increased levels of T~H~1 cells and T~H~1 cytokine IFNγ in SM of obese mice, we examined effects of T~H~1 on SM cell metabolic fucntions and inflammation. IFNγ is known to signal through JAK/STAT1 pathway involving activation of JAK1/JAK2 kinases. Consistently, P-STAT1 protein levels were increased in SM of HFD-fed WT mice compared to lean WT ([Supplemental Figure 8A](#SD1){ref-type="supplementary-material"}), whereas obese mice with ablation of T~H~1 (TCRb−/− mice)^[@R40]^ did not show increased P-STAT1 in SM (data not shown). To further study the effect of T~H~1 cells on muscle inflammation and metabolic functions, we performed *in vitro* experiments using murine C2C12 myofibers. Treatment of differentiated C2C12 cells with T~H~1-conditioned medium for 48 hours significantly upregulated MCP-1, RANTES, IL-6, and TNFα expression ([Supplemental Figure 8B](#SD1){ref-type="supplementary-material"}) and increased both STAT1 mRNA and P-STAT1 protein levels ([Supplemental Figure 8C](#SD1){ref-type="supplementary-material"}). The addition of anti-IFNγ antibody attenuated T~H~1-induced inflammation and P-STAT1 induction ([Supplemental Figures 8B--C](#SD1){ref-type="supplementary-material"}), indicating the effect of T~H~1 cells was mainly attributable to IFNγ. T~H~1 treatment also caused significant reductions in insulin-stimulated P-Akt ([Supplemental Figure 8D](#SD1){ref-type="supplementary-material"}), suggesting insulin resistance, in C2C12 myocytes. Treatment of C2C12 cells with nonspecific JAK inhibitor reduced T~H~1-induced P-STAT1 ([Supplemental Figure 8D](#SD1){ref-type="supplementary-material"}), attenuated T~H~1-mediated upregulation of proinflammatory IL-6, TNFα, MCP-1, and RANTES. ([Supplemental Figure 8B](#SD1){ref-type="supplementary-material"}), and improved T~H~1-induced insulin resistance, as shown by increased P-Akt level ([Supplemental Figure 8D](#SD1){ref-type="supplementary-material"}).

JAK1/JAK2 inhibitor baricitinib reduces T cell accumulation and activation in SM and improves insulin sensitivity {#S27}
-----------------------------------------------------------------------------------------------------------------

We next examined effects of T~H~1 cell/cytokine-pathway on inflammation and metabolic functions in vivo by treating obese mice with baricitinib, a selective JAK1/JAK2 inhibitor, which blocks IFNγ-induced signaling.^[@R47]^ Treatment of obese WT mice with baricitinib for 3 weeks reduced the expression of T-cell related markers, such as CD4, CD8, RANTES, IL-2, and IFNγ, in both "muscle" and PMAT ([Figures 6A--B](#F6){ref-type="fig"}) and significantly decreased the number of T cells, including CD4+ and CD8+ T cells, but not macrophages, in SM ([Figure 6C](#F6){ref-type="fig"}). These changes were accompanied by improved insulin resistance in HFD-fed mice after baricitinib treatment, compared with vehicle, indicated by significantly enhanced blood glucose clearance following an insulin injection ([Figure 6D](#F6){ref-type="fig"}). Together these results provide the first in vivo evidence that T~H~1 cells may induce SM inflammation and insulin resistance involving a JAK/STAT mechanism.

DISCUSSION {#S28}
==========

Our results suggested that the adipose tissue depots associated with SM---IMAT and PMAT---may play a role in obesity-induced SM inflammation and insulin resistance. We showed that T cells, together with macrophages, primarily accumulate in IMAT/PMAT. The increase in macrophage numbers in SM-associated IMAT/PMAT occurs during the early stage of obesity and precedes T cell accumulation. The induction of T cells in SM of obese mice was reduced by inhibition of CD11a. T cells polarized into proinflammatory T~H~1 in obese conditions, while T~reg~ cells were diminished. T~H~1 cells secrete IFNγ and induce myocyte inflammation and insulin resistance via activation of the JAK/STAT pathway. Indeed, inhibition of JAK/STAT pathway reduced inflammatory pathway activation and the production of chemokines in cultured myocytes. In vivo, targeting JAK/STAT pathway using the JAK1/JAK2 inhibitor baricitinib attenuated obesity-associated RANTES, IL-2, and IFNγ expression, reduced T cell infiltration in both "muscle" and PMAT, and improved insulin sensitivity.

We show here that in addition to macrophage accumulation previously described in the literature,^[@R1],[@R20]^ SM in obesity was also characterized by increased T cell accumulation. T cells were significantly increased after 8 weeks on HFD, whereas macrophages were upregulated after only 2 weeks on HFD. Our results thus suggest an early infiltration of macrophages in obese SM, followed by accumulation of T cells, which may contribute to SM metabolic dysfunction at a later stage of obesity. We previously reported that mice lacking αβ T cells did not show macrophage infiltration in SM upon HFD feeding.^[@R40]^ We speculate that T cells residing in SM of lean WT mice may play an important role in attracting early infiltration of macrophages into SM during obesity and that deficiency of "resident" T cells in SM of αβT cell--deficient mice may have attributed to the lack of macrophage infiltration into SM of these mice.

Although accumulation of immune cells was also observed between muscle bundles, macrophages and T cells were primarily located in EMAT of obese mice. This observation may explain the inconsistent results of human studies reported in the literature. Low macrophage and T cell numbers in human SM biopsies may be attributable to the location of biopsies and whether the overlying PMAT was trimmed before analysis. These results are important for future research done in human subjects. Similar to VAT, the majority of immune cells in IMAT/PMAT were located within crown-like structures.^[@R48]^ Consistent with our histological findings, we showed significantly higher proinflammatory cytokine and chemokine gene expression in PMAT compared to "muscle." The induction of macrophage markers in PMAT occurred earlier in the course of HFD feeding compared to "muscle" connected to it, suggesting that infiltration of immune cells into EMAT may initiate SM inflammation in obesity.

T cells and macrophages residing in PMAT and IMAT may exert effects on the neighboring myocytes via a paracrine mechanism and induce the expression of proinflammatory chemokines, such as MCP-1 and RANTES, further mediating blood monocyte and T lymphocyte migration into SM.^[@R49],[@R50]^ T cell trafficking may be mediated by a combination of chemokines and adhesion molecules, such as CD11a.^[@R51]^ CD11a−/− mice, as well as mice treated with CD11a-neutralizing antibody, had decreased T cell content, likely attributable to reduced T cell migration into SM. Obese CD11a−/− mice had attenuated inflammatory gene expression, which may reflect the effect of T cells on macrophage and SM cell cytokine production, as we recently reported in VAT.^[@R40],[@R42]^ Our findings not only provide a potential mechanism of T cell transmigration into SM, specifically EMAT, but also show an important role of T cells in obesity-induced SM inflammation. Future study needs to determine the "signals" (such as chemokines) in SM that promote T cells infiltration.

Our previous study revealed an important role of αβ T cells in obesity-associated SM inflammation.^[@R40]^ To study αβ T cells in SM in more detail, we quantified both CD4+ and CD8+ T cell subsets and revealed that obesity increased both CD4+ and CD8+ T cell numbers. Similar to VAT,^[@R52]^ we found that within the CD4+ T cell population, T~reg~ cells were markedly decreased, while T~H~1 cells were increased in SM of obese mice. IFNγ and CD4 gene expression were upregulated in both "muscle" and PMAT, but much greater increase in PMAT suggests that T~H~1 cells were located primarily in muscle tissue adipose depots. We hypothesized that proinflammatory mediators released by T~H~1 cells affect SM metabolic functions. Previous studies indicated that IFNγ contributes to adipocyte inflammation and insulin resistance through the JAK/STAT pathway.^[@R16],[@R53]^ Our study demonstrated that T~H~1 upregulated genes encoding inflammatory mediators, such as MCP-1, RANTES, IL-6, and TNFα, in myocytes and that this effect can be attributed to the presence of IFNγ. We observed that T~H~1-conditioned medium reduced insulin-stimulated Akt phosphorylation in C2C12 cells dependent on IFNγ. Inhibition of the JAK/STAT pathway attenuated T~H~1-induced inflammatory gene expression and restored insulin signaling in C2C12 myotubes. Consistent with these in vitro data and in vivo increases in T~H~1 cells, we found higher levels of P-STAT1 in SM of obese mice, which was associated with increased inflammation and decreased insulin sensitivity. More importantly, to show the relevance of IFNγ pathway in vivo, we used a selective JAK1/JAK2 inhibitor, baricitinib, currently in phase 3 clinical trials as a potential treatment for rheumatoid arthritis. Baricitinib administration resulted in marked reductions in SM T cells and IFNγ, the major Th1 cytokine, consistent with an essential role of STAT1 in initiating Th1 response.^[@R54]^ Despite marked T cell marker reduction, baricitinib treatment did not impact macrophage markers, which was unexpected because of an essential role of STAT1 in M1 polarization.^[@R55]^ We speculate that short-term treatment may not be sufficient to alter macrophage polarization in SM of obese mice. Along with the reduced T cell--related inflammation, inhibition of JAK/STAT pathway was also accompanied by improved insulin tolerance.

To our knowledge, we are the first to report the correlation of IMAT/PMAT in mouse leg muscle to HOMA-IR, SM T cell infiltration, and insulin resistance. A limitation of this micro-CT experiment is a relatively small sample size. Nevertheless, we showed large differences in total IMAT/PMAT between lean and obese mice. Our study highlights that rapid expansion of EMAT is associated with insulin resistance and SM inflammation. EMAT is a predominant location of T cells, along with macrophages, that accumulate in SM of mice with diet-induced obesity. T cells and macrophages further impair metabolic functions of SM cells through a paracrine mechanism. Specifically, proinflammatory T~H~1 cells may induce insulin resistance and increase inflammation in SM cells through a JAK/STAT mechanism.

In summary, the results of our study suggest that SM adipose depots (IMAT and PMAT) have altered phenotype, or "adiposopathy," similar to that observed in VAT, and may play an important role in the development of insulin resistance, diabetes, and inflammation associated with obesity.
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![Macrophages and T cells were elevated in SM of obese humans\
Quantitative RT-PCR was performed to analyze the expression of macrophage markers (CD11b, CD11c, and MCP-1) and T cell markers (CD3, CD4, CD8, and RANTES) in vastus lateralis muscle biopsies of lean (n=15) and obese (n=12) individuals. \*P\<0.05 compared to lean controls.](nihms692630f1){#F1}

###### Macrophages and T cells increased during the course of HFD feeding

SM, consisting of muscle fibers, IMAT, and PMAT, was harvested from hind legs, enzymatically digested, and analyzed by flow cytometry to quantify numbers of (A) CD11b+F4/80+ macrophages, (B) CD11b+F4/80+CD11c+ proinflammatory macrophages, and (C) CD3+ T cells per g tissue. (D) Quantification of T cell subsets in SM of lean and obese mice, including CD4+ T cell number and CD8+ T cell number per g tissue (n=10 mice/group), and CD4+CD25+FoxP3+ (T~reg~) cells (n=5 mice/group) and CD4+IFNγ+ (T~H~1) cells (n=6 mice/group) expressed as % CD4+ T cells. \*P\<0.05, \*\*P\<0.01, \*\*\*P\<0.001 compared to ND.
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###### Macrophages and T cells accumulated in PMAT and IMAT of HFD-fed mice

Quadriceps SM with IMAT and adherent PMAT were harvested from ND- and HFD-fed mice. (A) Location and representative H&E staining of quadriceps with PMAT and IMAT from HFD-fed mice, 10× magnification. Immunohistochemical staining of SM for (B) macrophages (Mac3, arrows) and (C) T cells (CD3, arrows) under 10× magnification (left panel) and 40× magnification (right panel). RNA was isolated from PMAT and "muscle," which includes muscle fiber and IMAT, of ND- and HFD-fed mice (n=10 mice/group). (D) Quantitative RT-PCR analysis of macrophage markers (F4/80 and CD11c), T cell markers (CD3, CD4, and CD8), and cytokines/chemokines (TNFα, IFNγ, MCP-1, and RANTES). \*P\<0.05, \*\*P\<0.01, \*\*\*P\<0.001. Student\'s t-test was performed to compare gene expression in PMAT or "muscle" between ND and HFD groups; two-way ANOVA was used to assess HFD-induced changes between PMAT and "muscle."
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###### EMAT expansion during 20 weeks of HFD is accompanied by inflammatory cell infiltration

Expression of genes encoding macrophage markers F4/80 and CD11c and T cell marker CD3 in (A) quadriceps "muscle" and (B) "PMAT" from mice fed ND or HFD for 2--20 weeks (n=3--6 mice/group). \*P\<0.05, \*\*P\<0.01, \*\*\*P\<0.001 for comparisons between diets at the indicated time point.
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###### CD11a deficiency reduced obesity-associated SM inflammation and T cell accumulation

\(A\) mRNA levels of inflammatory genes in SM of WT and CD11a−/− mice examined by quantitative RT-PCR (n=8 mice/group). (B) Numbers of CD3+, CD8+, and CD4+ T cells and CD11b+F4/80+ and CD11b+F4/80+CD11c+ macrophages per gram SM tissue harvested from HFD-fed CD11a−/− and WT mice (n=4 mice/group). HFD-fed WT mice were injected with KBA, a neutralizing anti-mouse CD11a antibody, or IgG control every other day for 9 times (n=4 mice/group), and SM from hind legs was harvested to analyze (C) the number of CD3+, CD8+, and CD4+ T cells and CD11b+F4/80+ and CD11b+F4/80+CD11c+ macrophages per gram tissue by flow cytometry (n=8 mice/group) and (D) relative mRNA levels of CD3, a total T cell marker, in "muscle" (left panel) and in PMAT (right panel). \#P=0.08, \*P\<0.05, \*\*P\<0.01 compared to HFD WT (control).
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###### The effect of selective JAK1/JAK2 inhibition on SM inflammation and insulin sensitivity in HFD-fed mice

Obese WT mice were administered a selective JAK1 and JAK2 inhibitor, baricitinib, in a dose of 10 mg/kg or vehicle control by oral gavage for 21 days. RNA was isolated from PMAT and "muscle" of baricitinib- and vehicle control--treated HFD-fed mice (n=8 mice/group). RT-PCR analysis of T cell markers in (A) "muscle" and (B) PMAT. Flow cytometry was performed to quantify the numbers of total CD3+, CD4+, and CD8+ T cells and CD11b+F4/80+ and CD11b+F4/80+CD11c+ M1 macrophages per gram tissue (n=5 mice/group) in (C) SM of vehicle control-- and baricitinib-treated mice. (D) Intraperitoneal insulin tolerance test (1.5 U/kg) (n=5 mice/group). \*P\<0.05, \*\*P\<0.01. Two-way ANOVA was performed to compare the response to insulin in vehicle control-- and baricitinib-treated mice.
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###### 

Pearson correlation coefficients for extramyocellular adipose tissue and insulin resistance

  ---------------------------------------------------------------------------------------------------
  Adipose\     Body\        Abdominal\   Abdominal\   Glucose     Insulin     HOMA-\      P-\
  Tissue       Weight       VAT          SAT                                  IR          Akt/Akt
  ------------ ------------ ------------ ------------ ----------- ----------- ----------- -----------
  Thigh\       0.827\       0.799\       0.649\       0.888\      0.610\      0.729\      −0.794\
  IMAT/PMAT    (p=0.011)    (p=0.018)    (p=0.082)    (p=0.003)   (p=0.108)   (p=0.040)   (p=0.060)

  Calf\        0.738\       0.697\       0.754\       0.456\      0.923\      0.863\      −0.547\
  IMAT/PMAT    (p=0.037)    (p=0.055)    (p=0.031)    (p=0.256)   (p=0.001)   (p=0.006)   (p=0.261)

  Total\       0.894\       0.859\       0.740\       0.884\      0.743\      0.834\      −0.827\
  IMAT/PMAT    (p=0.0028)   (p=0.006)    (p=0.036)    (p=0.004)   (p=0.035)   (p=0.010)   (p=0.042)

  Abdominal\   0.988\       ---          0.917\       0.693\      0.789\      0.784\      −0.968\
  VAT          (p\<0.001)                (p=0.001)    (p=0.057)   (p=0.020)   (p=0.021)   (p=0.002)
  ---------------------------------------------------------------------------------------------------

IMAT/PMAT: intermuscular adipose tissue/perimuscular adipose tissue; VAT: abdominal visceral adipose tissue; SAT: abdominal subcutaneous adipose tissue. P-Akt: serine^473^-phosphorylated Akt; Pearson correlation coefficients were computed with SAS 9.3 (pooled analysis, n=8).
